Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Company to launch product after the expiry of semaglutide patent in India
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Subscribe To Our Newsletter & Stay Updated
